Spherical agglomeration to improve dissolution and micromeritic properties of an anticancer drug, Bicalutamide.
Dalvadi H, Parmar K, Yadav S.
Drug Dev Ind Pharm · journal article · DOI 10.1080/03639045.2019.1585447 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för bicalutamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarRetraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630-640. https://doi.org/10.1002/ijc.20917.
Författaruppgift saknas
Int J Cancer · retraction notice · DOI 10.1002/ijc.32130Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.
Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O.
Basic Clin Pharmacol Toxicol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcpt.12071Mechanistic studies on the synthesis of bicalutamide.
Asaad N, Fillery S.
Org Biomol Chem · journal article · DOI 10.1039/b815894kTreatment of bicalutamide-induced breast events.
Sieber PR.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/14737140.7.12.1773Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Wellington K, Keam SJ.
Drugs Aging · journal article · DOI 10.2165/00002512-200724020-00008Bicalutamide: clinical pharmacokinetics and metabolism.
Cockshott ID.
Clin Pharmacokinet · review; journal article · DOI 10.2165/00003088-200443130-00003Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP.
J Biol Chem · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1074/jbc.m203310200[The role of bicalutamide in the treatment of prostate cancer].
Stav SY, Segal G.
Harefuah · review; journal article; english abstractNew alternative treatment in hirsutism: bicalutamide 25 mg/day.
Müderris II, Bayram F, Ozçelik B, Güven M.
Gynecol Endocrinol · journal article · DOI 10.1080/gye.16.1.63.66Bicalutamide: in early-stage prostate cancer.
Carswell CI, Figgitt DP.
Drugs · review; journal article · DOI 10.2165/00003495-200262170-00006The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function.
Cockshott ID, Sotaniemi EA, Cooper KJ, Jones DC.
Br J Clin Pharmacol · comparative study; research-article; journal article · DOI 10.1111/j.1365-2125.1993.tb00373.x